article

1. CITED4 gene therapy protects against maladaptive cardiac remodeling after ischemia/reperfusion injury in mice..  Molecular therapy : the journal of the American Society of Gene Therapy.  32:3683-3694. 2024
2. Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human..  Science translational medicine.  16:-. 2024
3. Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series..  JACC. Heart failure.  12:795-809. 2024
4. Coronary Microvascular Function Following Severe Preeclampsia..  Hypertension (Dallas, Tex. : 1979).  81:1272-1284. 2024
5. Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia..  JAMA cardiology.  9:209-220. 2024
6. Intrinsic and Extrinsic Contributors to the Cardiac Benefits of Exercise..  JACC. Basic to translational science.  9:535-552. 2023
7. Association of activin A and postpartum blood pressure in peripartum cardiomyopathy..  Pregnancy hypertension.  60-66. 2023
8. Cardioprotective and Anti-Inflammatory Effects of FAM3D in Myocardial Ischemia-Reperfusion Injury..  Circulation research.  133:651-653. 2023
9. Restoration of Cardiomyogenesis in Aged Mouse Hearts by Voluntary Exercise..  Circulation.  146:-. 2022
10. Animal Models of Exercise From Rodents to Pythons..  Circulation research.  130:1994-2014. 2022
11. Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models..  Circulation research.  130:1906-1925. 2022
12. Plasma Proteomics of COVID-19-Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics..  JACC. Basic to translational science.  7:425-441. 2022
13. Matrix Gla Protein Levels Are Associated With Arterial Stiffness and Incident Heart Failure With Preserved Ejection Fraction..  Arteriosclerosis, thrombosis, and vascular biology.  42:e61-e73. 2021
14. Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics..  Research square.  2021
15. Frailty and Post-hospitalization Outcomes in Patients With Heart Failure With Preserved Ejection Fraction..  The American journal of cardiology.  84-93. 2021
16. Gelatin Methacryloyl Bioadhesive Improves Survival and Reduces Scar Burden in a Mouse Model of Myocardial Infarction..  Journal of the American Heart Association.  9:-. 2020
17. Exercise training reverses cardiac aging phenotypes associated with heart failure with preserved ejection fraction in male mice..  Aging cell.  19:-. 2020
18. Targeting Age-Related Pathways in Heart Failure..  Circulation research.  126:533-551. 2020
19. Activin type II receptor signaling in cardiac aging and heart failure..  Science translational medicine.  11. 2019
20. Pulmonary Artery Mass in a Patient With Tuberculous Pericarditis..  CASE (Philadelphia, Pa.).  3:2-5. 2019
21. Cardiac macrophages promote diastolic dysfunction..  The Journal of experimental medicine.  215:423-440. 2018
22. IRF3 and type I interferons fuel a fatal response to myocardial infarction..  Nature medicine.  23:1481-1487. 2017
23. Why Don't We Have Proven Treatments for HFpEF?.  Circulation research.  120:1243-1245. 2017
24. The Role of Exercise in Cardiac Aging: From Physiology to Molecular Mechanisms..  Circulation research.  118:279-95. 2016
25. Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia..  Nutrition, metabolism, and cardiovascular diseases : NMCD.  23:836-42. 2012
26. Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology.  25:2731-9. 2011
27. Cardiac presentation of anaplastic large-cell lymphoma..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  28:e314-6. 2010
28. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling..  Proceedings of the National Academy of Sciences of the United States of America.  107:4669-74. 2010
29. Tissue-engineered arterial grafts: long-term results after implantation in a small animal model..  Journal of pediatric surgery.  44:1127-32; discussion 1132-3. 2009
30. Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model..  Annals of surgery.  248:370-7. 2008
31. Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology.  22:3888-95. 2008
32. Functional small-diameter human tissue-engineered arterial grafts in an immunodeficient mouse model: preliminary findings..  Archives of surgery (Chicago, Ill. : 1960).  143:488-94. 2008
33. Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model..  Biomaterials.  29:1454-63. 2007
34. Centrifugal seeding increases seeding efficiency and cellular distribution of bone marrow stromal cells in porous biodegradable scaffolds..  Tissue engineering.  13:2743-9. 2007
35. Construction of an autologous tissue-engineered venous conduit from bone marrow-derived vascular cells: optimization of cell harvest and seeding techniques..  Journal of pediatric surgery.  42:198-202. 2007